All News

Here, Scott Mazza, Founder of Vitality CBD, compares the effects of the cannabis compounds CBD and THC for use with various conditions.

The Senate’s latest attempt at legal medical cannabis access for patients was added to a bill on hemp regulations.

Let’s take a look at the most recent webinars on cannabis research and medicine to catch up on industry trends and innovations.

An executive order from the governor pardoned a significant number of cannabis convictions, noting the efforts to rectify harms from past cannabis policies.

This article, originally published by our sister brand LCGC International, summarizes an analysis and profiling of samples of illegal cannabis crops in Messina, Italy.

The smoking accessories company has partnered with the Science of Smokability study to advance research on cannabis smoking quality and consistency.

This month’s Healer webinar discussed several studies on cannabis and symptoms of dementia and cognitive decline.

This webinar discussed the research on the synergy of THC and D-limonene, discussing a study that found vaporized D-limonene reduces THC-induced anxiety.

Nebraska advocates are a few weeks away from knowing if two medical cannabis measures have enough signatures to qualify to appear on the 2024 ballot.

Three new positions were created to streamline and improve licensing processes, social equity, and more.

The new law eliminates the 37% excise tax for medical cannabis cardholders for certain products.

Willow Industries recently partnered with the Cannabis Research Coalition to advance cannabis research.

For the third time in recent years, the option to legalize recreational cannabis will be placed before voters in the Mount Rushmore State.

The Cannabis for Private Purposes Act legalizes cannabis for adults while prohibiting public consumption, sales, and detailing measures for protecting children.

A recently added amendment to the 2024 Farm Bill would significantly impact intoxicating hemp-derived products.

This webinar from MM411 explored the far-ranging studies of Dr. Raphael Mechoulam and Dr. Ethan Russo on the science and medicine of cannabis and other plants.

The latest webinar from the GMP Collective discussed the practice of lab shopping and the various causes, effects, and potential solutions.

The nonprofit, which is focused on advancing the cannabis industry, joins a network of industry experts from over a hundred different organizations.

The final installment of this webinar series discussed recommendations for new policies integrating cannabis into harm reduction efforts.

At the Cannabis Science Conference Spring 2024, toxicologist Cristelle Santos provided a deep dive into the need for better cannabis product safety standards.

This hour-long webinar covered consumer safety, interstate commerce, and the need for global standards, highlighting collaboration and evidence-based approaches for future regulatory frameworks.

Here we present a roundup of the interviews, insights, and presentation coverage from both before and during this year’s conference in Kansas City, Missouri from May 7-9, 2024.

In this interview at the Cannabis Science Conference, James Wylde, President and CEO of Greenlight Analytical, discusses new cannabis cultivation tools.

Focusing on the potential effects for medical cannabis patients, Americans for Safe Access held a high-level presentation and discussion on the rescheduling of cannabis.

The US Attorney General has initiated the process to reclassify cannabis from a Schedule I to a less-restrictive Schedule III substance.

At the Cannabis Science Conference, Antonio Timoteo Jr., PhD, presented research on cannabis cultivation practices and optimizing terpene content.

In the Cultivation Track at Cannabis Science Conference, Bernie Lorenz, Chief Science Officer of ProKure Solutions, discussed the intriguing topic of the effects of COVID on cannabis testing methods.

In the General Session of the Cannabis Science Conference, Scheril Murray Powell, Esq. and John Calloway Jr. discussed the many ways equity ties into science in the cannabis industry.

Multiple sources have reported that the US Drug Enforcement Administration will move to reclassify marijuana from Schedule I to Schedule III, effectively recognizing medical uses of cannabis and its reduced potential for abuse compared with other drugs.

In the second installment in this webinar series, Dr. Marion McNabb and Dr. Peter Grinspoon discuss implementation of cannabis as a harm reduction agent from a clinical perspective.